Alzheimer's Disease
Access to anti-amyloid treatment for Alzheimer’s patients requires new care paradigm
PHILADELPHIA — Safe and effective ways to introduce anti-amyloid medications for Alzheimer’s disease depends on comprehensive care infrastructure from screening to administration, according to a speaker.
Sleep habits likely play role in cognitive, neurological conditions
PHILADELPHIA — Better sleep boosts quality of life and may have positive long-reaching benefits including reduction of risk for neurological disorders, according to research presented at the American Neurological Association annual meeting.
Alzamend Neuro submits IND for bipolar disorder therapeutic
A clinical-stage biopharmaceutical company has announced the submission of an investigational new drug application to the FDA based upon results of a phase 2a clinical study of a novel lithium delivery system, AL001, for bipolar disorder.
BLOG: Neurotrophins hold the key to unlock diseases of the brain, eye
As a neuroscientist, biochemist and molecular biologist, I’m interested in the biosynthesis and regulation of neurotrophic factors, including nerve growth factor and brain-derived neurotrophic factor.
Q&A: AI identifies key social determinants of health for patients with dementia
Artificial intelligence could help clinicians address the social needs of patients with dementia, according to Elham Mahmoudi, PhD.
Blood test boosts diagnostic accuracy for Alzheimer’s by calculating amyloid probability
C2N Diagnostics released the PrecivityAD2 blood test, which uses positron emission tomography scans and cerebrospinal fluid tests to assist in accurate diagnosis for those presenting with signs or symptoms of Alzheimer’s disease.
Denali Therapeutics announces discontinuation of Alzheimer’s drug trial
A Bay Area clinical research and development firm announced it will discontinue development of a novel therapeutic for Alzheimer’s disease.
Anti-amyloid drug shows significant immune response in adults with mild Alzheimer’s
Treatment with an investigational anti-amyloid therapeutic for adults with mild Alzheimer’s disease was safe, efficacious and demonstrated a significant immune response up to 78 weeks, per a study published in EBioMedicine.
Partnership to utilize AI for early detection of Alzheimer’s disease, related dementias
A neuroscience company and an emerging artificial intelligence technology firm have announced a partnership that aims to boost access to routine brain care and to facilitate early detection of Alzheimer’s disease and related dementias.
Q&A: Proposed changes to Alzheimer’s diagnostic criteria could be ‘game changer’ for PCPs
At the recent Alzheimer's Association International Conference in Amsterdam, an Alzheimer’s Association workgroup proposed revisions to the diagnostic criteria for Alzheimer’s disease.